Rheumatology treats musculoskeletal and autoimmune diseases, including arthritis, lupus, gout, and vasculitis.
Send us all your questions or requests, and our expert team will assist you.
Current pharmacological management of Sjögren’s syndrome is stratified into symptomatic relief and systemic disease modification. For dryness, “secretagogues” are employed. These are medications like pilocarpine and cevimeline that stimulate the muscarinic receptors on the glands, forcing any remaining functional tissue to produce more fluid. While effective for symptoms, they do not alter the course of the autoimmune attack. Topical cyclosporine or lifitegrast eye drops are used to reduce inflammation specifically on the ocular surface, helping to increase tear production and heal corneal damage.
For systemic disease modification, clinicians turn to immunosuppressants. Hydroxychloroquine (an antimalarial) is the foundational therapy for most patients, used to treat fatigue and joint pain and to lower the overall inflammatory burden. For more severe organ involvement (lung, kidney, nerve), more potent agents such as methotrexate, azathioprine, or mycophenolate mofetil are utilized. These drugs work by broadly suppressing immune system activity to prevent further tissue damage.
Biologic therapies are the frontier of pharmacological management. Rituximab, a monoclonal antibody that depletes B-cells, is used in severe cases, particularly for vasculitis or lymphoma. Other biologics targeting B-cell-activating factor (BAFF) are under investigation. The goal is to move from broad suppression to targeted interruption of the specific pathways driving the disease, balancing efficacy with the risk of infection associated with immune suppression.
Regenerative medicine introduces a novel modality focused on immunomodulation and tissue repair. Mesenchymal Stem Cells (MSCs) are the primary agents used. These cells are harvested from bone marrow, adipose tissue, or umbilical cord tissue. In the context of Sjögren’s, MSCs are investigated for their ability to reset the immune system. They possess a unique capacity to inhibit the proliferation of autoreactive T-cells and B cells while promoting the expansion of regulatory T cells (Tregs), which maintain immune tolerance.
Systemic administration of MSCs (intravenous infusion) targets generalized autoimmune dysregulation. Clinical studies and compassionate use protocols have explored this for patients with severe fatigue and extraglandular involvement. The rationale is that MSCs will home to sites of inflammation and release anti-inflammatory cytokines (such as IL-10 and TGF-beta), thereby dampening the “cytokine storm” that drives the disease.
Localized administration involves injecting MSCs directly into the submandibular or lacrimal glands, often under ultrasound guidance. This approach aims to deliver a high concentration of trophic factors directly to the damaged tissue. The hope is not just to stop inflammation but also to stimulate the gland’s resident stem cells to regenerate acinar (fluid-producing) cells. This represents a shift from “saving what is left” to “rebuilding what was lost,” although the extent of proper regeneration depends on the severity of the pre-existing fibrosis.
Recognizing that the therapeutic effect of stem cells is primarily mediated by the molecules they secrete, research is pivoting towards “cell-free” therapies. Exosomes are nano-sized vesicles released by stem cells that contain lipids, proteins, and genetic material (miRNA). These vesicles act as mail carriers, delivering regenerative instructions to recipient cells.
In Sjögren’s syndrome, exosome therapy offers several theoretical advantages. Exosomes are smaller and can penetrate tissues more easily than whole cells. They carry lower risks of immune rejection or ectopic tissue formation. The “secretome,” the complete cocktail of factors secreted by stem cells, contains potent anti-fibrotic and pro-angiogenic (blood vessel forming) factors.
Applications include using exosome-rich solutions as advanced eye drops or localized injections. By delivering these factors into the glandular microenvironment, the therapy aims to reduce epithelial cell apoptosis (cell death) and restore tight junctions, which are crucial for secretory function. This area of regenerative medicine is rapidly evolving to develop standardized, off-the-shelf biological products that can manage the disease without the logistical complexity of handling live cells.
Platelet-Rich Plasma (PRP) is an autologous therapy where the patient’s own blood is concentrated to isolate platelets, which are rich in growth factors. In ophthalmology, PRP eye drops (often called serum tears) are a well-established regenerative treatment for severe dry eye that is unresponsive to conventional artificial tears. The growth factors in the serum, such as Epithelial Growth Factor (EGF) and Vitamin A mimic the properties of natural tears much better than saline-based drops. They promote the healing of the corneal epithelium and reduce ocular surface inflammation.
Beyond eye drops, PRP is being explored for intraglandular injection. The concept is similar to its use in orthopedics: inject a concentrated healing signal into damaged tissue. For inflamed salivary glands that are not fully atrophied, PRP injections stimulate local repair processes and improve blood flow. This is a “biologic scaffold” approach that provides the nutrients and signals necessary for the tissue to maintain its function.
The advantage of PRP is its safety profile, as it is derived entirely from the patient’s own blood. It avoids the risks of allergic reactions or disease transmission. For Sjögren’s patients, who often have multiple chemical sensitivities, this autologous nature is particularly appealing. It bridges the gap between palliative care and advanced cellular therapy.
Effective management of Sjögren’s syndrome requires an integrated approach that combines medical treatment with lifestyle adaptation. This includes close collaboration between the rheumatologist, ophthalmologist, and dentist.
Nutritional support is also part of the medical strategy. Omega-3 fatty acid supplementation is routinely recommended for its systemic anti-inflammatory effects and specific benefit to the tear lipid layer. Management of comorbidities is crucial; treating the hypothyroidism or fibromyalgia that often co-exists with Sjögren’s improves the overall clinical picture.
The “Treat to Target” philosophy is emerging in Sjögren’s care. This means setting specific quantifiable goals, such as a reduction in the ESSDAI score (a disease activity index) and adjusting therapy until those goals are met. This proactive stance ensures that the patient does not languish in uncontrolled low-grade inflammation, thereby maximizing long-term preservation of organ function.
Send us all your questions or requests, and our expert team will assist you.
Secretagogues are prescription medications, such as pilocarpine (Salagen) and cevimeline (Evoxac), designed to stimulate the salivary and sweat glands. They work by activating specific receptors (muscarinic receptors) on the gland cells, thereby increasing fluid production. They are effective for relieving dry mouth in patients with some residual glandular function, helping improve swallowing and oral comfort.
Serum tears are made from the patient’s own blood. The red blood cells are removed, leaving the serum, which is diluted and used as eye drops. Unlike artificial tears, serum contains biological components, such as growth factors, vitamins, and immunoglobulins, that mimic the composition of natural tears. These components help repair surface damage to the eye and reduce inflammation, offering relief for severe cases where standard drops fail.
Stem cell therapy, particularly using Mesenchymal Stem Cells (MSCs), has the potential to modulate the immune system and stop the autoimmune attack on the glands. Research suggests that these cells can “reset” the immune environment from an inflammatory to a regulatory state. Additionally, they may secrete factors that support the survival and repair of the remaining glandular tissue, potentially improving dryness and systemic symptoms like fatigue
Hydroxychloroquine (Plaquenil) is an antimalarial drug widely used in autoimmune diseases such as lupus and Sjögren’s syndrome. It helps to modulate the immune system without suppressing it too heavily. It is primarily prescribed to treat systemic symptoms such as joint pain, fatigue, and rashes, and to lower overall inflammatory markers in the blood. It is generally considered a foundational, long-term medication for the disease.
Punctal plugs are tiny, biocompatible devices inserted by an ophthalmologist into the puncta (tear drainage ducts) of the eyelids. By blocking the drainage of tears away from the eye, they help retain whatever natural or artificial tears are on the eye’s surface for an extended period. This simple, reversible procedure helps maintain moisture and improve comfort for patients with significant aqueous deficiency.
Your Comparison List (you must select at least 2 packages)
